PedAM
Pediatric Disease Annotations & Medicines
| Disease | lung cancer |
| Phenotype | C0011847|diabetes |
| Sentences | 20 |
| PubMedID- 22619084 | However, we did a sensitivity analysis by further adjusting for these factors and found that the results were attenuated slightly, but the risk of lung cancer associated with diabetes requiring insulin treatment remained significant (1.61 [1.08–2.39]). |
| PubMedID- 25169538 | Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis. |
| PubMedID- 26459254 | Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis. |
| PubMedID- 24148271 | Exclusion criteria were as follows: primary lesion <1 cm, histology confirmed as other than nsclc, type i diabetes, prior history of lung cancer or other cancer within the previous 5 years, previous therapy or surgical staging for nsclc before pet, massive or widespread metastatic tumors such that the primary focus could not be identified, and fdg-pet-ct scan performed more than one month prior to tissue diagnosis. |
| PubMedID- 22923670 | Objective: observational studies have associated metformin use with a decreased risk of lung cancer incidence in patients with type 2 diabetes, but the studies had important methodological shortcomings. |
| PubMedID- 24843722 | Among 14 cohort studies that reported an association between diabetes and the risk of lung cancer, 11 studies19 used incidence rate ratios as the measure of rr, and three studies18 used sir as the measure of rr. |
| PubMedID- 24051132 | Examining the association between statins and lung cancer incidence in patients with type 2 diabetes mellitus. |
| PubMedID- 24236069 | We excluded those who had diagnosis of systemic lupus erythematosus (sle), human immunodeficiency virus (hiv) infection, and lung cancer in patients with type 2 diabetes and control subjects. |
| PubMedID- 26288659 | Other studies have demonstrated the protective effect of tzds against the development of lung cancer in patients with diabetes [83, 84]. |
| PubMedID- 22895151 | Prolonged survival in lung cancer patients with diabetes mellitus. |
| PubMedID- 25661467 | Ho-1 expression can be induced when glucose concentrations are above 25 mm; however, the role of ho-1 in lung cancer patients with diabetes remains unknown. |
| PubMedID- 23431102 | (1) have reported that metformin use cannot correlate with decreased risk of lung cancer in patients with type 2 diabetes (rate ratio 0.94; 95% ci 0.76–1.17). |
| PubMedID- 22266734 | Conversely, diabetes was associated with improved lung cancer survival compared with those without diabetes (hr 0.84 [0.77–0.92]). |
| PubMedID- 26526071 | Furthermore, the association of lung cancer with diabetes [19] and dyslipidemia [20–22] has been reported. |
| PubMedID- 24924771 | Conclusions: this analysis demonstrated that metformin use may reduce lung cancer risk in patients with diabetes but not in a smoking-adjusted subgroup and that insulin use may be associated with an increased lung cancer risk in subjects with diabetes. |
| PubMedID- 26255998 | The relative importance of out-of-pocket cost was consistently lower in the hypothetical context of a new lung cancer diagnosis compared with diabetes or the patient's current health. |
| PubMedID- 26457130 | Background: published data suggest that diabetes influences survival of patients with lung cancer. |
| PubMedID- 21964531 | Survival in lung cancer with and without diabetes mellitus was compared using the kaplan-meier method and cox regression model for each study and the studies combined. |
| PubMedID- 26244663 | This screening process would improve the drug response for those particular subsets of patients and even be able to treat lung cancer patients with type ii diabetes with a single pparγ ligand. |
| PubMedID- 26063645 | Prognosis of small cell lung cancer patients with diabetes treated with metformin. |
Page: 1